Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHA: 600436)

Zhangzhou Pientzehuang Pharmaceutical., Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	10,887	10,036	8,674	8,004	6,493	5,706
Other Revenue	22.31	22.31	19.52	17.29	18.28	16.34
Revenue	10,909	10,058	8,694	8,022	6,511	5,722
Revenue Growth (YoY)	12.72%	15.69%	8.38%	23.20%	13.78%	20.06%
Cost of Revenue	6,056	5,363	4,735	3,968	3,584	3,198
Gross Profit	4,853	4,695	3,959	4,054	2,926	2,524
Selling, General & Admin	1,071	1,150	814.41	1,027	982.2	796.23
Research & Development	197.05	232.35	230.03	199.51	97.55	119.43
Other Operating Expenses	45.43	70.77	71.96	72.05	53.23	45.86
Operating Expenses	1,337	1,465	1,110	1,306	1,135	964.29
Operating Income	3,516	3,230	2,849	2,748	1,792	1,560
Interest Expense	-37.62	-37.31	-38.01	-32.9	-27.39	-31.13
Interest & Investment Income	167.44	170.81	171.62	144.48	149.27	95.31
Currency Exchange Gain (Loss)	3.09	3.09	7.18	-3.28	-3.27	4.69
Other Non Operating Income (Expenses)	8.19	6.02	-36.47	-21.62	-4.4	-2.73
EBT Excluding Unusual Items	3,657	3,373	2,954	2,834	1,906	1,626
Impairment of Goodwill	-	-	-	-	-	-6.1
Gain (Loss) on Sale of Investments	12.4	8.32	-0.02	4.54	6.72	-0.01
Gain (Loss) on Sale of Assets	4.57	1.31	11.14	27.59	40.29	4.59
Asset Writedown	-1.01	-	-0.33	-1.02	-	-
Other Unusual Items	-13.42	-13.42	13.18	3.55	26.08	20.43
Pretax Income	3,659	3,369	2,978	2,869	1,979	1,645
Income Tax Expense	554.63	517.77	454.76	404.23	289.54	257.66
Earnings From Continuing Operations	3,105	2,851	2,523	2,465	1,689	1,387
Minority Interest in Earnings	-25.42	-53.79	-50.63	-32.9	-17.84	-12.56
Net Income	3,079	2,797	2,472	2,432	1,672	1,374
Net Income to Common	3,079	2,797	2,472	2,432	1,672	1,374
Net Income Growth	9.02%	13.15%	1.66%	45.49%	21.62%	20.25%
Shares Outstanding (Basic)	604	603	603	603	603	603
Shares Outstanding (Diluted)	604	603	603	603	603	603
Shares Change (YoY)	0.24%	-0.02%	-0.07%	0.00%	0.11%	-0.32%
EPS (Basic)	5.10	4.64	4.10	4.03	2.77	2.28
EPS (Diluted)	5.10	4.64	4.10	4.03	2.77	2.28
EPS Growth	8.77%	13.17%	1.74%	45.49%	21.49%	20.63%
Free Cash Flow	1,007	2,065	6,698	370.11	1,048	-944.81
Free Cash Flow Per Share	1.67	3.42	11.11	0.61	1.74	-1.57
Dividend Per Share	2.320	2.320	1.250	1.210	0.900	0.820
Dividend Growth	85.60%	85.60%	3.31%	34.44%	9.76%	36.67%
Gross Margin	44.49%	46.68%	45.54%	50.53%	44.95%	44.11%
Operating Margin	32.23%	32.11%	32.77%	34.25%	27.52%	27.25%
Profit Margin	28.23%	27.81%	28.44%	30.32%	25.67%	24.02%
Free Cash Flow Margin	9.24%	20.53%	77.04%	4.61%	16.10%	-16.51%
EBITDA	3,599	3,298	2,897	2,854	1,882	1,615
EBITDA Margin	32.99%	32.79%	33.32%	35.58%	28.90%	28.23%
D&A For EBITDA	83.16	67.82	47.36	106.25	90.21	55.89
EBIT	3,516	3,230	2,849	2,748	1,792	1,560
EBIT Margin	32.23%	32.11%	32.77%	34.25%	27.52%	27.25%
Effective Tax Rate	15.16%	15.37%	15.27%	14.09%	14.63%	15.67%
Revenue as Reported	10,909	10,058	8,694	8,022	6,511	5,722
Advertising Expenses	-	531.48	255.04	445	473.79	342.12

Source: S&P Capital IQ. Standard template. Financial Sources.